The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the ...

Tirzepatide is also the compound in the diabetes drug Mounjaro. Advertising Even before the FDA approval, some doctors have ...

The FDA approval comes amid growing discussion about the potential uses of weight loss drugs beyond treating obesity and ...

And as of December 20, Eli Lilly’s weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...

The FDA approval for sleep apnea is ... That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug also saw reductions in blood pressure and ...